1. Meeting the needs of patients with ultrarare diseases;Crooke;Trends Mol Med,2022
2. n-Lorem Foundation Notes Latest in Guidance from FDA on Developing ASO Drug Products for Patients With Nano-Rare Diseases. Guidance Issued by FDA Provides a Supportive Environment to Develop Experimental ASO Medicines for Patients With Nano-Rare Disease;Crooke,2022
3. A case for n-of-1 trials—reply;Kravitz;JAMA Int Med,2019
4. Orphans in the market: the history of orphan drug policy;Mikami;Soc His Med,2017
5. Addressing the needs of patients with ultra-rare mutations one patient at a time: the n-lorem approach;Crooke;Nucleic Acid Ther,2021